Impact of obesity after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for rare peritoneal malignancies: Paradox of obesity or poor prognostic factor?
M AubertD MegeD GoereW EzzedineM PocardF QuenetR WernertO GlehenN Pirronull nullPublished in: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2024)
Obese patients have to be carefully managed after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for rare peritoneal malignancies. Some perioperative prophylactic treatments could be specifically implemented to reduce thromboembolic events, metabolic and wound complications.
Keyphrases
- obese patients
- prognostic factors
- minimally invasive
- weight loss
- bariatric surgery
- coronary artery bypass
- insulin resistance
- surgical site infection
- metabolic syndrome
- type diabetes
- roux en y gastric bypass
- high fat diet induced
- gastric bypass
- weight gain
- locally advanced
- metastatic renal cell carcinoma
- patients undergoing
- cardiac surgery
- risk factors
- atrial fibrillation
- coronary artery disease
- physical activity